Cell Biology, Immunology and Biochemistry (basic and preclinical research)
Larry Luchsinger, PhD
Associate Member, SVP and Chief Scientific Officer
New York Blood Center
New York, New York, United States
Disclosure(s): No financial relationships to disclose
Colleen Delaney, MD, MSc (she/her/hers)
Founder and Chief Scientific Officer
Deverra Therapeutics
seattle, Washington, United States
Disclosure(s): Coeptis Therapeutics: Full-time/Part-time Employee or Owner (Ongoing); Deverra Therapeutics: Full-time/Part-time Employee or Owner (Ongoing), Stock Shareholder (self-managed) (Ongoing)
Adam Wilkinson, PhD (he/him/his)
Associate Professor Of Stem Cell Biology
University of Oxford
Disclosure(s): No financial relationships to disclose
Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity. Mechanistic insights into HSC biology could be leveraged to further improve the strategies available to maintain and expand functional HSCs in vitro. Overcoming these hurdles is critical to effectively use HSCs for off-the-shelf allogeneic HSC transplantation or gene-editing of autologous HSCs for treatments of hematological disease and malignancies. In this session, we will discuss the most recent applications of HSC expansion technology currently in clinical use. We will also explore the latest mechanistic breakthroughs towards producing abundant HSCs in vitro for use in transfusion applications.
CABP CE Eligible